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Abstract
Myotonic dystrophy type 1 (DM1) is the most common hereditary myopathy in the adult
population. The disease is characterized by progressive skeletal muscle degeneration that produces
severe disability. At present, there is still no effective treatment for DM1 patients, but the
breakthroughs in understanding the molecular pathogenic mechanisms in DM1 have allowed the
testing of new therapeutic strategies. Animal models and in vitro two-dimensional cell cultures
have been essential for these advances. However, serious concerns exist regarding how faithfully
these models reproduce the biological complexity of the disease. Biofabrication tools can be
applied to engineer human three-dimensional (3D) culture systems that complement current
preclinical research models. Here, we describe the development of the first in vitro 3D model of
DM1 human skeletal muscle. Transdifferentiated myoblasts from patient-derived fibroblasts were
encapsulated in micromolded gelatin methacryloyl-carboxymethyl cellulose methacrylate
hydrogels through photomold patterning on functionalized glass coverslips. These hydrogels
present a microstructured topography that promotes myoblasts alignment and differentiation
resulting in highly aligned myotubes from both healthy and DM1 cells in a long-lasting cell culture.
The DM1 3D microtissues recapitulate the molecular alterations detected in patient biopsies.
Importantly, fusion index analyses demonstrate that 3D micropatterning significantly improved
DM1 cell differentiation into multinucleated myotubes compared to standard cell cultures.
Moreover, the characterization of the 3D cultures of DM1 myotubes detects phenotypes as the
reduced thickness of myotubes that can be used for drug testing. Finally, we evaluated the
therapeutic effect of antagomiR-23b administration on bioengineered DM1 skeletal muscle
microtissues. AntagomiR-23b treatment rescues both molecular DM1 hallmarks and structural
phenotype, restoring myotube diameter to healthy control sizes. Overall, these new microtissues
represent an improvement over conventional cell culture models and can be used as biomimetic
platforms to establish preclinical studies for myotonic dystrophy.
© 2021 The Author(s). Published by IOP Publishing Ltd
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1. Introduction
The skeletal muscle tissue is one of the largest organs
of the human body, and it is crucial for locomotion,
thermogenesis, and metabolism maintenance [1].
This tissue can be affected by several neuromuscu-
lar or metabolic disorders, such as myasthenia gravis
[2], McArdle disease [3], type 2 diabetes [4, 5], and
muscular dystrophies [6]. Muscular dystrophies are
genetically inherited degenerative disorders for most
ofwhich there is no cure to date. These disorders share
muscle weakness and wasting as common symptoms;
however, muscular dystrophies are very heterogen-
eous, differing in age of onset, rate of progression,
inheritance pattern, and type of muscles that are
affected [6–8]. The intrinsic heterogenicity of these
diseases makes the development of new therapies
especially challenging since it is expected that each
patient would have a different response to treatments.
Drug development for new muscular dystrophy
therapies usually involves the use of in vitro cell cul-
ture assays and in vivo animalmodels in phases before
clinical trials. These strategies have long contributed
to drug discovery by analyzing specific features of
biological processes and identifying the molecular
causes of certain diseases [9]. Still, both have sig-
nificant shortcomings that make it challenging to
obtain physiologically relevant results for humans.
For instance, conventional in vitro models involve
2D cell monolayers cultured on flat and rigid sub-
strates. These models do not emulate the complex-
ity of real tissues, which have a three-dimensional
(3D) structural organization of cells surrounded by
each other and an extracellular matrix [10]. On the
other hand, functional 3D tissues representing tissue
physiology can be found in animal models. The use
of animal models in pharmacological research raises
several ethical concerns. Moreover, in vivo models
often fail to predict the clinical efficacy of drugs. This
is due to species-specific differences that limit the
extrapolation of animal data to human conditions
[11]. It has been estimated that following this drug
development pathway, only 11.8% of drugs entering
clinical trials become approved, generating a cost of
billions of dollars for newly authorized drugs [12,
13]. To accelerate preclinical research, in vitro stud-
ies could be complemented by human 3D culture sys-
tems. These in vitro systems consist of patient-derived
bioengineered skeletal muscle tissues that offer a bet-
ter representation of the environment of living tissues
with a particular 3D architecture [14].
Skeletal muscle architecture is characterized by
bundles of aligned muscle fibers (myofibers). These
fibers are formed by the fusion of muscle precursor
cells (myoblasts) into multinucleated myotubes,
which later become mature myofibers [15]. Because
of this complex architecture, engineering skeletal
muscle tissues requires a specific organization of
muscle precursor cells. These are usually embedded
in a suitable biomaterial scaffold, promoting dif-
ferentiation of myoblasts to form aligned myotubes
[16]. Moreover, the biomaterial should provide cells
with an appropriate 3D growth environment, optimal
oxygen levels, effective nutrient transport, and mech-
anical integrity over an extended culture period [10].
Hydrogels of natural origin, such as collagen, gelatin,
or fibrin, have been widely used as biomaterial scaf-
folds for engineered skeletal muscle [17]. This is
due to their high water content and the presence
of cell adhesion and degradation motifs, which allow
cell growth and matrix remodeling. Among these
hydrogels, gelatin methacryloyl (GelMA) and other
methacrylated biomaterials have been used to encap-
sulate cells in defined 3D structures due to their pho-
tocrosslinkable properties [18]. Also, these hydrogels
can further be combined with non-degradable bio-
materials, such as alginate or carboxymethyl cellulose.
The addition of these polysaccharides toGelMA com-
posite hydrogels enhances their mechanical prop-
erties and supports long-term culture of myotubes
[19–21].
In this work, we focused on developing the
first bioengineered 3D model of myotonic dys-
trophy type 1 (DM1) human skeletal muscle tissue.
DM1 is a life-threatening and chronically debilitat-
ing disorder, which is the most common heredit-
ary myopathy in adults (for a recent review of DM1
hallmarks see [22]). The genetic cause of DM1 is a
dynamicmutation that expands the cytosine-thymin-
guanine (CTG) triplet repeat in the 3′ non-translated
region of the Dystrophia Myotonica Protein Kinase
(DMPK) gene [23]. Cytosine-uracil-guanine (CUG)
repeat RNAs accumulate in nuclear foci. This mutant
DMPK RNA causes toxic gene misregulation events
at the level of gene expression [24, 25], translation
[26], gene silencing [27–30], alternative splicing [31–
33], and polyadenylation of subsets of transcripts
[34]. Muscleblind-like (MBNL) proteins, a family
of alternative splicing regulators, are sequestered in
these CUG foci, and concomitantly their molecu-
lar function is impaired [35]. This results in abnor-
mal alternative splicing events directly related to sev-
eral disease characteristic symptoms, such as muscle
weakness and hyper contraction.
Although significant advances have been made in
studying themolecular causes of DM1, there is still no
effective treatment for patients. Animal models, such
as mouse [36], fly [37–39], and zebrafish [40], have
been used to evaluate different therapeutic candidates
[41–45]. Among these, therapeutic gene modulation
is a promising strategy that has the objective of regu-
lating the endogenous expression of a gene tomitigate
a certain disease [46]. Following this approximation,
it has been demonstrated that microRNAs (miRs)
that inhibit MBNL translation can be silenced by
antisense oligonucleotides (antagomiRs). Concretely,
specific blocking of miR-218 and miR-23b has resul-
ted in increased MBNL protein levels and rescue of
2
Biofabrication 13 (2021) 035035 X Fernández-Garibay et al
mis-splicing events in DM1 human myoblasts [46]
and HSALR DM1 model mice, where low toxicity,
high efficacy, and long-lasting biological effects were
observed [46, 47]. While these are encouraging res-
ults, the effectiveness of treatments for DM1 still
needs to be investigated in clinical phases.
Here, we describe a method to fabricate a bioen-
gineered 3D DM1 skeletal muscle tissue model using
transdifferentiated myoblasts from patient-derived
fibroblasts. These cells were encapsulated in micro-
patterned GelMA-carboxymethyl cellulose methac-
rylate (CMCMA) hydrogels on top of functional-
ized glass coverslips. Cells were cultured for up to
three weeks obtaining alignedmyotubes with disease-
associated molecular and structural phenotypic fea-
tures. Remarkably, cell encapsulation in micropat-
terns improved DM1 myotube formation compared
to traditional 2D cultures. Moreover, the analysis
of 3D reconstructed myotubes showed that DM1
myotubes have a thinner phenotype than myotubes
from healthy control cells. Additionally, as a proof-
of-concept, we showed that antagomiR treatment
for miR-23b could rescue MBNL expression and
myotube diameter in 3D DM1 human myotubes.
Overall, we demonstrate that patient-derived bioen-
gineered DM1 skeletal muscle microtissues represent
valuable in vitro tools for preclinical research. Finally,
the developed fabrication method for DM1 could
easily be translated for drug development and other
studies on muscular dystrophies.
2. Experimental procedure
2.1. Cell culture
Immortalized human fibroblasts from unaffected
control and DM1 patient (carrying 1300 CTG
repeats quantified in the blood cells) [48] were
kindly provided by Dr Denis Furling and Dr Vin-
cent Mouly (Institute of Myology, Paris). Fibro-
blast cells were grown in Dulbecco’s modified eagle
medium (DMEM, 4.5 g l−1 glucose, Gibco) sup-
plemented with 1% penicillin-streptomycin (P/S,
10 000 U ml−1, Thermofisher) and 15% fetal bovine
serum (Gibco). Transdifferentiation into myoblast-
like cells was induced by turning on the myogenic
program, forcing MyoD expression when cultur-
ing cells in muscle differentiation medium (MDM).
MDM consisted of DMEM with 4.5 g l−1 gluc-
ose, 1% P/S, 2% horse serum, 1% apo-transferrin
(10 mg ml−1), 0.1% insulin (10 mg ml−1), and
0.02% doxycycline (10 mg ml−1). In all cases, cells
were grown at 37 ◦C in a humidified atmosphere
containing 5% CO2. For cell differentiation in 2D,
fibroblasts were seeded at 12 000 cells cm−2 in 12-
well plates containing glass coverslips coated with
50 µg ml−1 collagen type I and were cultured in
growth medium. Once the cells were confluent, the
growth medium was replaced by MDM to induce
the myogenic program. Fusion index was analyzed in
cultures differentiated for seven days.
2.2. Microstructured stamps fabrication
Microstructured poly(dimethylsiloxane) (PDMS),
Sylgard™ Elastomer base and curing agent) stamps
were fabricated by replica molding of silicon wafer
molds.
2.2.1. Microfabrication of silicon molds
Silicon wafer molds were fabricated by standard
photolithography techniques using SU-8 negative
photoresist. Briefly, silicon wafers (4′′ n-type <111>,
MicroChemicals GmbH) were cleaned in a plasma
chamber for 20 min at 6.8 W. After that, wafers were
heated for 5 min in a hotplate at 95 ◦C to dehyd-
rate them. Negative resist SU-8 2100 (2100, Micro-
Chem) was spin-coated in two steps to obtain struc-
tures of 100 µm in height. To make the patterns,
a mask aligner (SÜSS Microtec, MJB4) was set to
240 mJ cm−2 energy radiation at 365 nm, and a high-
quality emulsion flexible film was used as a pho-
tomask (JD Photodata, UK). Irradiation time was
set to 20 s. Cross-linkage of negative-tone exposed
regions of SU-8 was subject to a hotplate cycle of
65 ◦C and 95 ◦C for 5 and 20 min, respectively.
The labile photoresist was removed by developing
the crosslinked patterns immersing the wafer in SU-8
developer (MicroChem) for 10 min. Then, the action
of 2-propanol stopped development. After a quick N2
blow, we heated the molds for 60 min at 120 ◦C. As
a final step, the SU-8 patterned silicon molds had to
undergo silanization to obtain hydrophobic surfaces
and avoid permanent bonding with the PDMS.
2.2.2. Replica molding of microstructured PDMS
stamps
The polymer elastomer base and curing agent were
weighted in a 10:1 ratio to obtain microstructured
stamps of 6mm in diameter, with channels of 100 µm
and 200 µm of width and height. After mixing thor-
oughly, we degassed the polymer in a vacuum cham-
ber. PDMS was poured on the patterned silicon sub-
strate and cured at 80 ◦C for 4 h. Finally, PDMS was
detached and cut off using a 5 mm biopsy punch.
PDMS stamps were cleaned by sonication in Milli-Q
water and 2-propanol for 5 min and dried using N2
flow before using them for tissue fabrication.
2.3. Prepolymer preparation
GelMA (figure 1(e)) and CMCMA (figure 1(g)) were
synthesized as previously described [19]. These pre-
polymer precursors and the photoinitiator lithium
phenyl (2,4,6-trimethylbenzoyl) phosphinate (LAP,
TCI Europe N.V.) were dissolved in MDM at 65 ◦C
for 2 h. The concentrations of GelMA, CMCMA and
LAP were fixed to obtain final concentrations of 5%,
1% and 0.1% (w/v), respectively.
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Figure 1. Fabrication protocol to obtain 3D skeletal muscle microtissues. (a), (c), (e), (g) Chemical structures of
(a) 3-(trimethoxysilyl)propyl methacrylate (TMSPMA), (c) poly(ethylene glycol) diacrylate (PEGDA), (e) gelatin methacryloyl
(GelMA) and (g) carboxymethyl cellulose methacrylate (CMCMA). (b) Schematic of silanization of glass coverslips by plasma
activation and treatment with TMSPMA. (d) Silanized coverslips were coated with a PEGDA layer. PEGDA was polymerized by
UV light exposure in the presence of a photoinitiator, lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate (LAP). (f), (h), (i)
Photomold patterning of cell-laden GelMA-CMCMA hydrogels. A microstructured poly(dimethylsiloxane) (PDMS) stamp (h)
was used to fabricate cell-laden micropatterned hydrogels on top of PEGDA-coated glass coverslips (i) by polymerization with UV
light.
2.4. Cell encapsulation in 3Dmicrostructured
hydrogels
Cell-laden 3Dmicrostructured hydrogels were fabric-
ated on top of glass coverslips using a photomold pat-
terning technique, as described in [20].
2.4.1. Glass coverslip functionalization
Glass coverslips were previously treated with
3-(trimethoxysilyl)propyl methacrylate (TMSPMA,
Aldrich) (figure 1(a)) and coated with a layer of poly-
ethylene glycol diacrylate (PEGDA, MW 4000 Da,
Sigma-Aldrich) (figure 1(c)) by free radical polymer-
ization. First, clean glass coverslips were activated
by oxygen plasma at 29.6 W for 30 s. Immedi-
ately after plasma treatment, the glass surface was
covered with a freshly prepared silanization solu-
tion (TMSPMA diluted in ethanol at 1:50 and
mixed with 3% acetic acid) for 1 h. Then, covers-
lips were thoroughly washed with ethanol and dried
(figure 1(b)).
For PEGDA coating, we prepared a solution of
20% (w/v) PEGDA and 2% (w/v) LAP in Milli-Q
water by dissolving in a water bath at 60 ◦C for
30min. For each coverslip, a 5µl dropwas placed on a
Teflon surface. Then, the silanized side of the covers-
lip was carefully pressed on top. Finally, samples were
exposed to UV for 2 min using a UVP Crosslinker
(model CL-1000 l, 365 nm, 40 W, Analytik Jena US),
washed several times with Milli-Q water, and thor-
oughly dried (figure 1(d)).
2.4.2. Cell encapsulation
To encapsulate cells in micropatterned hydrogels, we
mixed the prepolymer solution with a cell suspension
of either control or DM1 cells in MDM to obtain a
final concentration of 2.5 × 107 cells ml−1. Then, an
8 µl drop of the cell-laden prepolymer was placed on
a PEGDA-coated glass coverslip, and a PDMS stamp
(figure 1(h)) was pressed lightly on top, filling the
microchannels with the solution. The hydrogels were
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crosslinked by UV exposure of 30 s using the UVP
Crosslinker. MDM was added to each sample, and
stamps were carefully removed after 20 min of incub-
ation at 37 ◦C (figures 1(f) and (i)). Encapsulated
cells were differentiated for up to 21 days, with cul-
ture media being replaced every two days.
2.5. Hydrogel characterization
2.5.1. Stiffness measurements
The bulk stiffness of GelMA-CMCMA hydrogels was
analyzed by uniaxial compression tests using a Zwick
Z0.5 TN instrument (Zwick-Roell, Germany) with a
5 N load cell. Hydrogels were fabricated as described
in [20]. For each sample, 300 µl of the prepolymer
solution were placed in a 48-well plate and exposed
to UV light for 30 s. Cylindrical samples were cut
using a 10 mm diameter biopsy punch. Samples were
tested at room temperature (RT) up to 30% final
strain (deformation), using the following paramet-
ers: 0.1 mN preload force and 20%min−1 strain rate.
Force-deformation graphs were obtained using the
TestXpert (Zwick-Roell) software. Values for the com-
pressive modulus were automatically calculated from
the slope of the linear region corresponding to 10%–
20% deformation (strain) with the TestXpert soft-
ware.
To obtain Young’s modulus of the micropat-
terned GelMA-CMCMA hydrogels in liquid condi-
tions, samples were photomolded as described before
(see section 2.4). After 24 h of incubation at 37 ◦C, the
stiffness was measured by atomic force microscopy
(AFM) following a previously described protocol [49,
50]. Briefly, indentation measurements were conduc-
ted using a NanoWizard® 4 Bioscience AFM (JPK
Instruments) mounted onto a Nikon Ti inverted
microscope. Silicon nitride pyramidal tips (Nano-
World) with nominal spring constants of 0.08 Nm−1
were used. Series of ten indentations at a frequency of
0.05 Hz (10 µm amplitude) were performed in differ-
ent positions of the GelMA-CMCMA micropatterns.
Finally, the Hertz model for a pyramidal tip was fitted
to the measured force-distance curves, using the JPK
data analysis software.
2.5.2. Scanning electron microscopy (SEM) imaging
Hydrogels for SEM imaging were fabricated follow-
ing the same protocol as for compression measure-
ments. After 24 h of incubation, the hydrogels were
washed with Milli-Q water and fixed for 1 h in a
2.5% glutaraldehyde solution (Sigma-Aldrich). Fol-
lowing several washes, samples were dehydrated by
sequential immersion in graded ethanol solutions in
Milli-Q water. Washings of 10 min were performed
with 50%, 70% (×2), 90% (×3), 96% (×3) and
99.5% (×3) ethanol. To dry the hydrogels without
causing their collapse, samples were placed in a crit-
ical point drying chamber (K850, QuorumTechnolo-
gies, UK), where ethanol was completely replaced by
liquid CO2 and gradually heated until CO2 achieved
gas phase equilibrium and was slowly drained. After
critical point drying, microstructured hydrogels were
covered with Au and imaged by ultrahigh-resolution
SEM (Nova NanoSEM 230, FEI Company, The Neth-
erlands) operating in a low vacuum mode (0.5 mbar
of water vapor pressure).
2.6. Cell viability assay
Cell viability was evaluated 24 h after encapsulation
using the Live/Dead viability/cytotoxicity kit (Invitro-
gen). Briefly, samples were washed several times with
sterile 1× phosphate buffered saline (PBS) and incub-
ated for 30 min with a staining solution containing
Calcein AM, Ethidium homodimer-1, and Hoescht
(Invitrogen) in PBS. Cell viability was calculated as
the percentage of living cells with respect to the total
cell number analyzed in the 3D reconstruction of con-
focal Z-stacks using Imaris software.
2.7. Antisense oligonucleotide treatment
AntagomiR oligonucleotides (Creative Biogene)
were administrated 72 h after DM1 microtissue
fabrication. MDM was replaced and supplemen-
ted with 100 nM of AntagomiRs for miR-sc (con-
trol) or miR-23b-3p. The treatment lasted for
seven days without replacing the culture media.




GmUmA∗mC∗mA∗mA∗-3′-chol (sc control). Where
m denotes 2′-O-methyl-modified phosphoramidit-
ies, ∗ denotes phosphorothioate linkages, and chol
denotes cholesterol groups.
2.8. Fluorescence in situ hybridization (FISH)
Bioengineered 3D skeletal muscle tissues were fixed
in 4% paraformaldehyde for 30 min at RT and
washed with 1× PBS for 10 min. Samples were
incubated in the prehybridization buffer (2× saline
sodium citrate [SSC], 30% deionized formamide)
for 30 min at RT and hybridized with a Cy3-
(CAG)7-Cy3-labeled probe, diluted 1:200 in hybrid-
ization buffer (40% deionized formamide, 2× SSC,
10% dextran sulfate, 0.2% BSA, 2 mM Ribonucleos-
ide Vanadyl Complex (Sigma-Aldrich), 1 mg ml−1
Escherichia coli tRNA, 1% herring sperm DNA)
overnight at 37 ◦C in the dark. After hybridiza-
tion, samples were washed twice with a prehybrid-
ization buffer for 30 min at 42 ◦C, washed with
1X PBS, and incubated with DAPI for 15 min.
All the incubations were performed in a humidity
chamber.
2.9. Immunofluorescence staining
Bioengineered muscle tissues were fixed with 10%
formalin solution (Sigma-Aldrich) for 30 min at
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RT, followed by several washes in PBS. Samples
were then permeabilized with PBS-T (0.1% Triton-
X (Sigma-Aldrich) in PBS), blocked (0.3% Triton-X,
3% donkey serum (Sigma-Aldrich) in PBS) for 2 h
at RT, and incubated with primary antibody (sup-
plementary table 1 (available online at stacks.iop.org/
BF/13/035035/mmedia)) at 4 ◦C overnight. After sev-
eral PBS-Twashes, the samples were incubated for 2 h
with the fluorophore-conjugated secondary antibody
(supplementary table 1) at RT. Finally, the samples
were counterstained with DAPI (4′,6-diamidino-
2-phenylindole, Life Technologies) to detect the
nuclei.
For MBNL1 detection, after FISH protocol,
samples were incubated with the monoclonal anti-
MBNL1 primary antibody at 4 ◦C. The fluorescence
signal was amplified using a biotin-conjugated sec-
ondary antibody (supplementary table 1) and the
VECTASTAIN® Elite® ABC kit (Vector) for 1 h at
RT, followed by PBS-T washes and incubation with
either Dylight®488-FITC (1:200, Vector) for 2 h at
RT. Finally, the samples were counterstained with
DAPI to detect the nuclei.
2.10. Imaging
Light microscopy and live-cell imaging of myotubes
were performed using a Zeiss Axio Observer.Z1/7
outfitted with the XL S1 cell incubator. Imaging
was performed at 37 ◦C and 5% CO2. Fluores-
cence images were taken as Z-stacks with a ZEISS
LSM800 confocal laser scanningmicroscope and ana-
lyzed using the Imarismicroscope image analysis soft-
ware (Oxford instruments) and the Fiji image pro-
cessing package, a distribution of Image J [51, 52].
2.11. Fusion index andmyotube size analysis
Z-stacks were analyzed as 3D images using the
Imaris software. Fusion index was determined as
the percentage of nuclei in myotubes (⩾2 myo-
nuclei) with respect to the total number of nuc-
lei, in myotubes expressing sarcomeric α-actinin
(SAA). The diameter of individual 3D myotubes
was obtained by the object-oriented bounding box
statistical variable (BoundingBoxOO Length A),
which measures the length of the object’s shortest
principal axis.
2.12. RNA extraction, RT-PCR and real-time PCR
Total RNA from human bioengineered muscles was
isolated using Tri-reagent (Sigma) according to the
manufacturer’s instructions. One microgram of RNA
was digested with DNase I (Invitrogen) and reverse-
transcribed with SuperScriptTM II (Invitrogen) using
random hexanucleotides. qRT-PCR was carried out
on one nanogram of cDNA template with the FIRE-
Pol® EvaGreen® qPCR Mix Plus (Solis Biodyne) and
specific primers (supplementary table 2). GAPDH
andACTBwere used as endogenous controls. miRNA
expression was quantified using specific miRCURY
LNA microRNA PCR primers (Qiagen) according to
themanufacturer’s instructions. Relative gene expres-
sion was normalized to miR-103 expression [53].
Expression levels were measured using the Quant-
Studio 5 Applied Biosystems Real-Time PCR System.
Expression relative to the endogenous genes and con-
trol group was calculated using the 2−∆∆Ct method.
Pairs of samples were compared using two-tailed Stu-
dent t-tests (α = 0.05), applying Welch’s correction
when necessary. For splicing analyses, 20 ng of cDNA
were used in a standard PCR reaction with GoTaq
polymerase (Promega). Specific primers were used
to analyze alternative splicing of Bridging integrator
1 (BIN1), Nuclear Factor I X (NFIX), and Spectrin
Alpha Non-Erythrocytic 1 (SPTAN1) (supplementary
table 2).
2.13. Western blotting
For total protein extraction, samples were homogen-
ized in RIPA buffer (150 mM NaCl, 1.0% IGEPAL,
0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-
HCl pH 8.0) supplemented with protease and phos-
phatase inhibitor cocktails (Roche Applied Science).
Total proteins were quantified with a BCA protein
assay kit (Pierce) using bovine serum albumin as the
standard concentration range. For the immunodetec-
tion assay, 20 µg of samples were denatured for 5 min
at 100 ◦C, electrophoresed on 12% SDS-PAGE gels,
transferred onto nitrocellulose membranes 0.45 µm
(GE Healthcare), and blocked with 5% non-fat
dried milk in PBS-T (1× PBS; 0.05% Tween 20,
pH 7.4). Membranes were incubated overnight at
4 ◦C with primary mouse anti-MBNL1 (1:200, clone
MB1a (4A8), Developmental Studies Hybridoma
Bank) or mouse anti-MBNL2 (1:100, clone MB2a
(3B4), Developmental Studies Hybridoma Bank).
Anti-GAPDH-binding protein-horseradish peroxi-
dase (HRP) antibody (1 h, 1:3500, clone G-9, Santa
Cruz) as a loading control. All primary antibod-
ies were detected using HRP-conjugated anti-mouse-
IgG secondary antibody (1 h, 1:5000, Sigma-Aldrich).
Immunoreactive bands were detected using ECLTM
Western blotting substrate (Pierce), and images were
acquired with an AMERSHAM ImageQuant 800 (GE
Healthcare). Quantification was performed using
ImageJ software. The statistical differences were
estimated by the Student’s t-test (p < 0.05) on
normalized data.
2.14. Statistical analysis
All group data are expressed as mean ± SEM. The
comparisons between groups were performed using
Prism 8 software (GraphPad) by two-tailed Stu-
dent t-test (α = 0.05), applying Welch’s correction
when necessary. Differences between groups were
considered significant when P < 0.05 (∗P < 0.05;
∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001).
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3. Results and discussion
3.1. A fabrication protocol to obtain 3D skeletal
muscle microtissues
The skeletal muscle is a highly organized tissue made
up of arrays of aligned, multinucleated myofibers.
This complex architecture should be mimicked in
vitro to obtain 3D models that accurately repres-
ent the basic features of skeletal muscle tissue. Mul-
tinucleated myofibers are formed by fusion and
differentiation of muscle precursor cells; therefore,
fabrication strategies for tissue engineering should
provide effective topographical cues that favor myo-
blast alignment and fusion. Among these biofab-
rication techniques to engineer topographical cues,
the most used are micropatterning, micromolding,
electrospinning, and 3D bioprinting [54]. Previous
studies have shown that cells with a tendency to
align in vivo (e.g. fibroblasts, murine myoblasts, and
endothelial cells) can elongate and align in vitro if
they are geometrically confined within a suitable bio-
material [55]. Accordingly, our fabrication protocol
was designed to encapsulate humanmuscle precursor
cells in micropatterned hydrogels, which confine cells
in narrow hydrogel filaments and induce the forma-
tion of elongated myotubes.
As previously described, we used photomold
patterning to transfer the features of microstruc-
tured PDMS stamps into photocrosslinkable GelMA-
CMCMA hydrogels (figures 1 and 2(a)). We fab-
ricated stamps with channels of 200 µm (data not
shown) or 100 µm of width, height, and spacing. We
observed better cell alignment when cells were con-
fined in smaller structures. This was in agreement
with other studies where cell alignment and myotube
formation were enhanced in the thinnest structures
[56]. Besides alignment being favored in narrower
patterns, there are other limitations to the dimensions
of hydrogels for cell encapsulation. As some studies
point out, there is a limited diffusion of oxygen and
nutrients in engineered tissues at around 200 µm of
depth due to the lack of vascularization [19, 57, 58].
Therefore, we fabricated smaller structures to over-
come this limitation. Consequently, we decided to use
the microstructured stamps with smaller features to
fabricate hydrogel filaments of 100 µm in width and
5 mm in length on top of glass coverslips.
Using glass as our substrate, we noticed that some
cells adhered to the flat surface between hydrogel
filaments outside of the 3D structure (figure 2(b)).
This was an unwanted effect since cells in 2D would
grow and differentiate at a different speed, creating
two separate cell populations. To ensure that cells
remained confined within the 3D GelMA-CMCMA
hydrogel, the glass surface was previously silanized
and coated with a thin layer of PEGDA hydrogel.
PEGDA is hydrophilic and inert to protein adsorp-
tion [59]; hence, this surface modification highly
reduced undesired 2D cell attachment outside the
GelMA-CMCMAmicrofilaments fabricated on top of
the PEGDA layer (figure 2(c)). Furthermore, GelMA-
CMCMA was covalently attached to PEGDA, which
gave more stability to the micropatterned structures
[60].
Cell encapsulation in photocrosslinkable hydro-
gels is achieved by free radical polymerization in the
presence of a photoinitiator and UV light. Therefore,
after this procedure, cell survival strongly depends
on critical factors, including UV wavelength, energy
dose, and photoinitiator concentration. When cells
are exposed to a low dose of long-wave UV light, the
procedure is considered biocompatible [61]. As has
been reported, LAP photoinitiator has a high extinc-
tion coefficient at 365 nm, which makes it more effi-
cient than other commonly used compounds, such as
Irgacure 2659 [19, 62]. This efficiency allowed cross-
linking composite hydrogels with a very low pho-
toinitiator concentration and short exposure times
(low energy dose). To confirm this, we measured
the energy dose received by cells during 30 s of UV
exposure using a wireless power-meter inside the
UVP crosslinking chamber, obtaining 0.48 J cm−2
(16 mW cm−2 during 30 s). This energy dose is
very low, considering cell-laden GelMA hydrogels
have been crosslinkedwith energy doses ranging from
0.3 J cm−2 to 36 J cm−2 [63, 64]. Moreover, cell cyto-
toxicity assays (figures 3(a)–(h)) showed that more
than 88% of encapsulated cells remained viable 24 h
after UV exposure (figure 3(i)).
Although both 3D bioprinting and photomold
patterning are valuable biofabrication strategies for
generating cell-laden hydrogel filaments, photomold
patterning offered several advantages compared to
our previous 3D bioprinted model [19], such as
reproducibility, amount of material required, or the
final cost of the procedure.
Human skeletal muscle tissue models have been
developed from primary and immortalized human
myoblasts and human induced pluripotent stem cells
[65]. Bioengineered 3D in vitro models require large
numbers of cells, especially for high-throughput drug
screening platforms. This represents a challenge for
developing disease models, where it is necessary
to incorporate patient cells coming from muscle
biopsies. A major problem of using primary myo-
blasts from adult DM1 patients is their limited pro-
liferative capacity due to premature replicative senes-
cence [66]. Besides, muscle biopsies are invasive and
not always available. Arandel et al overcame these lim-
itations by developing transdifferentiated myotubes
cell lines [48]. These cell lines consisted of immortal-
ized skin fibroblasts that were converted into multi-
nucleated myoblasts by forcing the overexpression of
the myogenic regulator factor MYOD1. Here, we fab-
ricated 3D skeletal muscle microtissues from immor-
talized fibroblasts obtained from a healthy control
individual and a DM1 patient. Cell-laden hydrogels
were cultured in MDM containing doxycycline and a
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Figure 2. Effect of PEGDA coating on micromolded hydrogels. (a) Phase contrast image of cell-laden micropatterned hydrogels
(scale bar: 2.5 mm). (b), (c) Representative phase contrast images of cell-laden hydrogels without (b) and with (c) PEGDA coating
(scale bars: 200 µm).
Figure 3. (a)–(h) Representative images of live/dead staining from healthy control (a)–(d) and DM1 cells (e)–(h) 24 h after cell
encapsulation. Live cells were stained with Calcein AM (green), nuclei were stained by Hoescht (blue), and dead cells (red) were
stained with Ethidium homodimer-1 (EthD-1) (Scale bars: 100 µm). (i) Graph showing the cell viability in micromolded
hydrogels represented as the live cells over the total cell number (mean± SEM). (j) Example of a typical force-deformation curve
obtained by uniaxial compression tests on bulk GelMA-CMCMA hydrogels. Young’s modulus (E)= 0.6± 0.1 kPa (k) typical
force–displacement curves of the AFM tip indenting the surface of the GelMA-CMCMAmicrostructured hydrogels.
E= 0.5± 0.2 kPa (Mean values± SEM). (l)–(o) Scanning electron microscopy (SEM) images of GelMA-CMCMA (l), (m) and
PEGDA (n), (o) hydrogels. Scale bars: (l), (n) 5 µm, (m), (o) 1 µm.
low serum concentration from the moment of encap-
sulation. With this culture media, doxycycline activ-
ated the myogenic program and transdifferentiation
into myoblast-like cells. Additionally, the reduced
serum concentration slowed down cell proliferation,
inducing a shift to a differentiation state. Further-
more, myoblasts need to be close to recognize each
other and fuse into myotubes. Since cell prolifera-
tion was limited by the MDM, working with a high
cell density (2.5 × 107 cells ml−1) was key in obtain-
ing multinucleated myotubes. In summary, we have
developed a reproducible method to generate 3D
skeletal musclemicrotissues from human cells. In this
protocol, we applied a photomold patterning tech-
nique to encapsulate cells in GelMA-CMCMA hydro-
gel scaffolds.
3.2. Physical properties of GelMA-CMCMA
hydrogels
Skeletal muscle tissue engineering requires cul-
ture time for myoblast fusion and myotube mat-
uration. Additionally, engineered tissues should
remain viable for several weeks to be valuable for
drug screening applications. For these reasons, the
biomaterials used as scaffold need to resist enzymatic
degradation by encapsulated cells and other stress
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cues. We previously showed that degradation of
GelMA hydrogels could be slowed down by fab-
ricating composites that include a small percent-
age of a non-degradable polymer [19]. GelMA con-
tains cell adhesion and degradation sites that allow
cells to attach and remodel the matrix, a neces-
sary feature for cell spreading and fusion. CMCMA
is a biocompatible cellulose derivate that is non-
degradable by mammalian cells [67]. Therefore,
its incorporation into the hydrogel formulation
provided more structural stability over time. In fact,
in our previous works, we have demonstrated that
this composite hydrogel allowed long-lasting culture
and differentiation of murine skeletal muscle cells
[20, 68].
The bulk stiffness of GelMA-CMCMA hydro-
gels was measured using uniaxial compression tests,
obtaining a Young’s modulus of 0.6 ± 0.1 kPa
(figure 3(j)). To calculate the stiffness of our micro-
patterned hydrogels in liquid conditions, we per-
formed AFM microindentation measurements
(figure 3(k)). The obtained values were comparable
(E = 0.5 ± 0.2 kPa), corresponding to soft hydro-
gels in the range of 0.5–0.7 kPa. Some studies suggest
that the optimal stiffness for myotube maturation
is higher, being closer to the native skeletal muscle
tissue (∼12 kPa) [69, 70]. However, these experi-
ments were performed by seeding cells on top of 2D
substrates. In contrast, the stiffness of hydrogels for
3D skeletal muscle models varies depending on the
biomaterials used but lean towards softer hydrogels.
For instance, the encapsulation of human myoblasts
in fibrin-based hydrogels is performed in bioma-
terials with Young’s modulus of 1 ± 0.1 kPa [71].
Similarly, 3D studies performed with GelMA and
C2C12 murine cells indicated that softer hydrogels in
the range of 1–3 kPa lead to more elongated cell mor-
phology, better cell spreading, and greater differenti-
ation in 3D structures [20, 56]. In the case of micro-
patterned GelMA-based hydrogels, stiffer hydrogels
can be obtained by modifying fabrication conditions
to increase the crosslinking degree. We previously
studied cell morphology and spreading in micro-
patterned GelMA-CMCMA hydrogels with different
stiffness values [20]. Stellate morphology indicates
that cells can move better within the material, which
is essential for cell fusion. We observed that cells had
a stellate morphology in softer hydrogels, while most
cells were round when encapsulated using longer UV
exposure times. Furthermore, longer UV exposure
times or higher photoinitiator concentration may
affect cell viability (see section 3.1). Moreover, highly
crosslinked hydrogels result in densely packed fibrillar
structures that reduce water uptake and hinder nutri-
ent diffusion and transport [19, 72, 73]. The fibrillar
nanostructure of our photomolded GelMA-CMCMA
hydrogels was observed using SEM (figures 3(l) and
(m)). The images showed an interconnected porous
network that allows the diffusion of growth factors
and other biological substances through the hydro-
gel. Conversely, PEGDA hydrogel analysis in SEM
microscopy revealed that it is formed by a dense non-
porous matrix (figures 3(n) and (o)). This character-
istic structure in the PEGDA layer helps to avoid cell
growth and improves the adhesion and attachment of
the GelMA-CMCMA scaffold. Altogether, the phys-
ical properties of GelMA-CMCMAhydrogel scaffolds
are appropriate for supporting long-term cell culture
of skeletal muscle tissue.
3.3. 3Dmodel of DM1 retains molecular features of
the disease and provides a new structural
phenotype for preclinical research
In this work, we fabricated 3D skeletal muscle tis-
sue from human immortalized transdifferentiated
myoblast-like cells that present molecular and phen-
otypical features of DM1. By evaluating 2D cell
cultures, Arandel et al confirmed that patient-derived
cells present nuclear RNA aggregates (foci) of expan-
ded CUG repeats, a hallmark feature of DM1. They
also showed that DM1 cells had a reduced fusion
capability and formed smaller myotubes compared
to healthy controls in 2D [48]. To validate the use
of this cell line for our bioengineered DM1 model,
we analyzed if nuclear RNA aggregates were also
observed in 3D. By performing FISH and immuno-
fluorescence analyses, we demonstrated the presence
of CUGexp-RNA foci and their colocalization with
MBNL1 (figure 4), confirming that these cells retain
DM1-associated molecular characteristics and are
suitable for generating in vitro 3D models for the
disease.
To evaluate fusion capability in 3D, we assessed
confocal images of 2D cultures and bioengineered
microtissues from both control and DM1 myotubes.
After seven days in differentiation conditions, we
performed immunofluorescence stainings for myosin
heavy chain 7, SAA, and nuclei (figures 5(a)–(p)).
Then, we used confocal images to calculate the fusion
index, which is an indicator of differentiation qual-
ity in skeletal muscle cell cultures [74]. As expec-
ted, DM1 myoblasts in 2D culture had a significantly
lower fusion index than healthy controls. Unexpec-
tedly, when cells were encapsulated in 3D GelMA-
CMCMA hydrogels, there were no differences in
differentiation between healthy controls and DM1
cells, obtaining high fusion index values for both
cases (figure 5(q)). Remarkably, 3D micropattern-
ing resulted in the formation of long, multinucleated
myotubes from DM1 patient-derived cells after seven
days of culture, which is not possible to generate in
standard cell cultures.
Although the fusion index of 3D DM1 myotubes
was comparable to healthy myotubes, we observed
structural differences, which prompted us to ana-
lyze the myotube diameter. Bioengineered skeletal
muscle microtissues were differentiated for 7, 14, or
21 days before immunostaining for confocal imaging.
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Figure 4. Encapsulated DM1 cells present disease-associated molecular phenotypes. Representative confocal images of (a)–(d)
control and (e)–(h) DM1 immortalized transdifferentiated myoblast-like cells encapsulated in GelMA-CMCMA hydrogels. (a),
(e) Nuclei were stained with DAPI (blue). (b), (f) Nuclear RNA aggregates of expanded-CUG repeats (white arrows) were only
present in DM1 cells and detected by FISH using a Cy3-(CAG)7-Cy3 probe (red). (c), (g) MBNL1 stainings (green) showing a
reduced expression of MBNL1 in DM1 cells compared to controls. (d), (h) Merged images showing colocalization of MBNL1 with
nuclear CUGexp-RNA aggregates in DM1 transdifferentiated myoblast-like cells (Scale bars: 10 µm).
Then, the 3D reconstructions of myotubes express-
ing SAA (figures 6(a)–(f)) were used to measure the
individual diameter of control and DM1 myotubes
over time. Several works have quantified myotube
diameter in 2D for different purposes; for example,
to characterize patient cells [75], test different cul-
ture conditions [76], evaluate the influence of topo-
graphy in differentiation [77], or to study the effect
of administrating a given compound to myotubes
[78]. Myotube diameter has also been measured in
3D cultures; for instance, Khodabukus et al com-
pared myotube cross-sections to analyze the matur-
ation of electrically stimulated constructs [79]. Meas-
urements in all these cases were carried out manu-
ally, using tools from ImageJ software. In contrast,
our measurements were obtained by a 3D recon-
struction using Imaris software (figure 6(g)). With
this reconstruction, eachmyotube diameter was auto-
matically obtained with surface analysis tools. We
found that 3D DM1 myotubes have a reduced dia-
meter compared to healthy control myotubes (13.4
vs. 21.7 µm) after the first week of 3D culture
(figure 6(h)). After two weeks of culture, both types
of myotubes increased in size, but DM1 myotubes
continue to show a reduced diameter compared to
control myotubes. On the contrary, after three weeks
of culture, we did not detect differences between
the size of 3D myotubes. Nevertheless, this obser-
vation might not be due to a DM1 phenotype, but
the healthy myotubes have a reduced size after three
weeks as a potential senescence of the cultures. For
this reason, assays with these 3D muscle models
should be performed in myotubes cultured for less
than three weeks.
Previous works in DM1 cell models have
described deficient muscle differentiation. A reduced
fusion potential has been observed in 2D studies with
myoblasts from transgenic mice [80] and myogenic
satellite cells fromDM1 patients [81]. As an indicator
of muscle differentiation, the fusion index has been
used to investigate some aspects of DM1 molecular
pathology [82, 83]. It has also been applied to com-
pare DM1 vs. control cells while establishing cell lines
[48] and test if proposed treatments could restore
muscle differentiation [84]. Notably, we demon-
strated that 3D micropatterning improves the dif-
ferentiation of DM1 cells, obtaining fusion index
values that are similar to healthy controls. Thus, this
indicator cannot be applied to evaluate phenotype
rescue by a given therapy. Instead, we found a sig-
nificant difference in the diameter of 3D myotubes
fromDM1 and control cells. DM1 usually presents in
adulthood, when tissue is already formed. Therefore,
from a drug development perspective, the reduced
myotube diameter in 3D is a more physiologically
relevant phenotype than impaired fusion in 2D cul-
tures. Considering these results, we propose that this
new structural phenotype would be a better indicator
to assess the effects of DM1 therapies in preclinical
research.
3.4. AntagomiR treatments rescue bioengineered
3DDM1muscle phenotypes
Antisense oligonucleotides for specific blocking of
miR-23b (antagomiRs) have already shown efficacy
to increase MBNL protein levels in 2D DM1 myo-
blasts [46] as well as to rescue molecular pathology,
splicing events, and functional phenotypes in amouse
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Figure 5. Cell differentiation is improved in 3D cultures. (a)–(p) Representative confocal images of 2D (a)–(h) and 3D (i)–(p)
cultures stained for myosin heavy chain 7 (MYH7, green), sarcomeric α-actinin (SAA, red), and nuclei (DAPI, blue) after seven
days in differentiation conditions (scale bars: 50 µm). (q) Graph showing comparison of fusion index expressed as the percentage
of differentiated myotubes with respect to the total cell number. ∗∗∗∗p < 0.0001.
model [46, 47] .To demonstrate the application of our
bioengineered in vitro model of DM1 in preclinical
research, we evaluated the effect of this antagomiR in
our 3D cell cultures.
AntagomiR against miR-23b (α-miR-23b) or
a scrambled control (sc-control) antagomiR were
administered to bioengineered DM1 microtis-
sues by gymnotic delivery at a concentration of
100 nM. Of note, cells were already orientated
along the micropatterns and transdifferentiated into
myoblast-like cells at the moment of antagomiRs
administration. The treatment lasted for seven days.
To determine the success of the treatment, we ana-
lyzed the expression levels of miR-23b by real-time
PCR (figure 7(a)). We observed a reduction of miR-
23b expression in DM1 3D muscles treated with α-
miR-23b compared to the DM1 3D muscles treated
with sc-control antagomiR. Next, we investigated if
silencing miR-23b enhanced MBNL transcripts in
the bioengineered 3D microtissues. We found an
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Figure 6. 3D DM1 myotubes have a reduced myotube diameter. (a)–(f) Representative confocal images of bioengineered 3D
human skeletal muscle microtissues from healthy control (a)–(c) and DM1 (d)–(f) cells cultured for up to 21 days (Scale bars:
50 µm). Myotubes expressing SAA were stained in red and nuclei were counterstained with DAPI (blue). The 3D reconstruction
of DM1 microtissues (g) was used to measure the individual diameter of myotubes over culture time (h). ∗p < 0.05 and
∗∗∗∗p < 0.0001.
increase in MBNL2 transcripts in 3D DM1 myotubes
treated with α-miR-23b compared to sc-control-
treated tissues. However, MBNL1 was not increased
at the transcriptional level (figure 7(b)). Of note,
western blot quantification showed an increase in
both MBNL1-2 proteins in bioengineered micro-
tissues treated with α-miR-23b (figures 7(c) and
(d)). To determine if the increase of MBNL pro-
teins rescue characteristic DM1 spliceopathy, we
analyzed the exon inclusion (Percentage Spliced
In; PSI) of two MBNL1-dependent splicing events:
BIN1 and NFIX; and one MBNL2-dependent spli-
cing event: SPTAN1. Remarkably, the exon inclusion
was significantly rescued for the three splicing events
(figures 7(e) and (f)). These rescue levels are lower
than those obtained by transfection of antagomiRs
in 2D myoblasts in previous studies [46]. This can
be explained by the different delivery strategies
used. Gene silencing by oligonucleotides usually
requires a delivery vehicle to perform cell trans-
fection. This requirement comes with several chal-
lenges that can complicate the development of oli-
gonucleotide therapies [85]. As an alternative, gym-
notic delivery (‘naked’ delivery of oligonucleotides to
cells) has been promising in recent years. With this
delivery approach, cells in culture are exposed to a
constant concentration of oligonucleotides, similar
to what happens in vivo when plasma and tissues
are exposed to saline-formulated oligonucleotides.
Transfection strategy allows the internalization of
large amounts of oligonucleotides. Nevertheless,
gymnotic delivery remains a more physiologically
relevant delivery approach, and its effects can
be improved by dosage optimization in future
assays.
Finally, to assess the effect of antagomiRs on the
DM1 3D structural phenotype, we measured the
diameter of 3D myotubes treated with α-miR-23b
and compared them to sc-control-treated myotubes
(figure 7(g)). After seven days of treatment, we
found that sc-control-treated microtissues had a
mean myotube diameter of 14.4 µm, similar to
DM1 myotubes without any treatment. Remarkably,
upon treatment with α-miR-23b, myotubes reached
a mean diameter of 21.9 µm (figure 7(h)), com-
parable to the diameter of myotubes from healthy
control cells (figure 6(h)). Altogether, these results
highlight the application of our bioengineered in
vitro 3D model to assess DM1 therapies. Other anti-
sense oligonucleotides and other potential therapies
like small molecules or peptides can be tested on
this platform. Furthermore, drug effects can be ana-
lyzed at different levels, including transcriptional,
post-transcriptional, and structural phenotype
changes.
4. Conclusions
In this work, we described a detailed protocol for
fabricating 3D skeletal muscle microtissues that can
be maintained in long-lasting cultures. This micro-
molding technique is cheap and can be easily repro-
duced. Importantly, cell encapsulation in GelMA-
CMCMA micropatterned hydrogels produce highly
aligned multinucleated myotubes. Using this pro-
tocol, we generated for the first time a bioengin-
eered human 3D skeletal muscle model for myotonic
dystrophy. Remarkably, this protocol can be applied
to cells from patients for different muscle diseases
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Figure 7. Therapeutic effect of antagomiR-23b on a bioengineered in vitro 3D model of DM1 human skeletal muscle. (a)
Real-time PCR quantification of miR-23b expression after seven days of treatment with 100 nM of antagomiR-23b (α-miR-23b)
or scrambled control antagomiR (sc-control). U1 and U6 snRNAs were used as reference genes. (b) qRT-PCR quantification of
MBNL1 and MBNL2 expression relative to GAPDH and ACTB genes. (c), (d) Western blot quantification of MBNL1 and MBNL2
protein expression levels in 3D DM1 myotubes seven days after treatment with 100 nM of α-miR-23b or sc-control. GAPDH
expression was used as endogenous control. (e), (f) RT-PCR analyses of splicing events altered in BIN1, NFIX, and SPTAN1 in 3D
DM1 myotubes. (g), (h) Confocal images of DM1 myotubes after treatment with sc-control (g) or α-miR-23b (h). Myotubes
expressing SAA were stained in red and nuclei were counterstained with DAPI (blue) (scale bars: 50 µm). (i) Quantification of the
diameter of 3D DM1 myotubes treated with sc-control or α-miR-23b. The shaded area corresponds to the mean of myotube
diameter of healthy control myotubes after 7 (bottom limit) and 14 days (top limit) of differentiation. ∗p < 0.05, ∗∗p < 0.01 and
∗∗∗∗p < 0.0001.
(i.e. other muscular dystrophies) to obtain patient-
specific models. DM1 patient-derived cells encap-
sulated in GelMA-CMCMA hydrogels present DM1
molecular characteristics and correctly differenti-
ated into multinucleated myotubes. A reduced fusion
index, an indicator of muscle differentiation, is a
typical feature of DM1 standard 2D cultures. Not-
ably, the fusion index is restored to control val-
ues in DM1 3D myotubes. However, DM1 3D
microtissues display a new structural phenotype;
the 3D diameter of myotubes is significantly thin-
ner than control myotubes. Therefore, this more
physiological phenotype of the bioengineered 3D
DM1 myotubes can be used for drug screening stud-
ies of DM1. To evaluate the applicability of this in
vitromodel in evaluating therapeutic compounds, we
treated the bioengineered 3D microtissues with anti-
sense oligonucleotides against miR-23b. Our findings
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indicated that antagomiRs for miR-23b are able to
rescue molecular and structural phenotypes of DM1
disease when administrated to bioengineered 3D
muscle. Overall, we demonstrated that our patient-
derived 3Dmodel is a relevant alternative to the exist-
ing in vitro and animal models. These bioengineered
3D skeletal muscle microtissues could be useful in a
preclinical platform for DM1 drug development.
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